Ab­b­Vie looks to shed Al­ler­gan's lega­cy wom­en's health unit as it hun­kers down for Hu­mi­ra biosim dooms­day — re­port

With the clock tick­ing on its block­buster Hu­mi­ra patent in the US, Ab­b­Vie is re­port­ed­ly in talks to sell the $5 bil­lion women’s health port­fo­lio it ac­quired from Al­ler­gan in or­der to pay off debt and fo­cus on new ar­eas.

Un­named sources told Reuters  that Ab­b­Vie is work­ing with Mor­gan Stan­ley to auc­tion off the port­fo­lio, which in­cludes the Lo Loestrin Fe birth con­trol pill. The po­ten­tial sale has re­port­ed­ly at­tract­ed the likes of CVC Cap­i­tal Part­ners, which the sources say is eye­ing the unit for its port­fo­lio com­pa­ny, Ther­amex.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.